Yidong Liu1, Zheng Liu1, Qiang Fu1, Zewei Wang1, Hangcheng Fu1, Weisi Liu1, Yiwei Wang2, Jiejie Xu3. 1. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. 2. Department of Urology, Ninth People׳s Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. Electronic address: wang_yiwei@yeah.net. 3. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. Electronic address: jjxufdu@fudan.edu.cn.
Abstract
PURPOSE: Galectin-9, a member of the "tandem repeat" type galectins performing as animal lectins with an affinity for β-galactosides, has been well documented to exert crucial functions in immunomodulation, survival, and growth of various tumors. This study aims to reveal the clinical significance of galectin-9 in urothelial carcinoma of the bladder (UCB) postoperatively. MATERIALS AND METHODS: We retrospectively included 202 patients with UCB who underwent radical cystectomy at a single institute from 2002 to 2014. Galectin-9 expression was assessed by immunohistochemistry on tissue microarrays. The Kaplan-Meier method was conducted to plot survival curves. Prognostic nomograms were constructed via integrating all the independent indicators from multivariate Cox analysis for recurrence-free survival (RFS) and cancer-specific survival (CSS). In addition, we evaluate whether patients with increased or decreased galectin-9 expression might benefit from adjuvant chemotherapy. RESULTS: Low galectin-9 expression was significantly correlated with lymphovascular invasion (P = 0.002), early recurrence (P = 0.010), and short CSS (P = 0.002). Furthermore, multivariate analysis identified galectin-9 expression as a potential independent indicator for RFS (hazard ratio = 0.62; 95% CI: 0.40-0.95; P = 0.030) and CSS (hazard ratio = 0.46; 95% CI: 0.26-0.81; P = 0.008). Moreover, the benefit associated with adjuvant chemotherapy was superior among galectin-9 low patients than among galectin-9 high patients (P = 0.014). CONCLUSIONS: Expression of galectin-9 is an independent prognostic factor for RFS and CSS in patients with UCB. Evaluation of galectin-9 expression may predict the benefit from adjuvant chemotherapy.
PURPOSE:Galectin-9, a member of the "tandem repeat" type galectins performing as animal lectins with an affinity for β-galactosides, has been well documented to exert crucial functions in immunomodulation, survival, and growth of various tumors. This study aims to reveal the clinical significance of galectin-9 in urothelial carcinoma of the bladder (UCB) postoperatively. MATERIALS AND METHODS: We retrospectively included 202 patients with UCB who underwent radical cystectomy at a single institute from 2002 to 2014. Galectin-9 expression was assessed by immunohistochemistry on tissue microarrays. The Kaplan-Meier method was conducted to plot survival curves. Prognostic nomograms were constructed via integrating all the independent indicators from multivariate Cox analysis for recurrence-free survival (RFS) and cancer-specific survival (CSS). In addition, we evaluate whether patients with increased or decreased galectin-9 expression might benefit from adjuvant chemotherapy. RESULTS: Low galectin-9 expression was significantly correlated with lymphovascular invasion (P = 0.002), early recurrence (P = 0.010), and short CSS (P = 0.002). Furthermore, multivariate analysis identified galectin-9 expression as a potential independent indicator for RFS (hazard ratio = 0.62; 95% CI: 0.40-0.95; P = 0.030) and CSS (hazard ratio = 0.46; 95% CI: 0.26-0.81; P = 0.008). Moreover, the benefit associated with adjuvant chemotherapy was superior among galectin-9 low patients than among galectin-9 high patients (P = 0.014). CONCLUSIONS: Expression of galectin-9 is an independent prognostic factor for RFS and CSS in patients with UCB. Evaluation of galectin-9 expression may predict the benefit from adjuvant chemotherapy.
Authors: Elizabeth Ann L Enninga; Kyriakos Chatzopoulos; John T Butterfield; Shari L Sutor; Alexey A Leontovich; Wendy K Nevala; Thomas J Flotte; Svetomir N Markovic Journal: J Pathol Date: 2018-06-28 Impact factor: 7.996
Authors: Kamil Wdowiak; Tomasz Francuz; Enrique Gallego-Colon; Natalia Ruiz-Agamez; Marcin Kubeczko; Iga Grochoła; Jerzy Wojnar Journal: Int J Mol Sci Date: 2018-01-10 Impact factor: 5.923
Authors: Patricia M R Pereira; Sheryl Roberts; Flávio Figueira; João P C Tomé; Thomas Reiner; Jason S Lewis Journal: J Nucl Med Date: 2020-01-31 Impact factor: 10.057
Authors: Florent Colomb; Leila B Giron; Thomas A Premeaux; Brooks I Mitchell; Toshiro Niki; Emmanouil Papasavvas; Luis J Montaner; Lishomwa C Ndhlovu; Mohamed Abdel-Mohsen Journal: Front Immunol Date: 2019-02-20 Impact factor: 7.561
Authors: Min Zhang; Xin Zhang; Minghang Yu; Wei Zhang; Di Zhang; Song Zeng; Xi Wang; Xiaopeng Hu Journal: Front Oncol Date: 2021-07-27 Impact factor: 6.244
Authors: Paula Dobosz; Przemysław A Stempor; Jason Roszik; Amir Herman; Adi Layani; Raanan Berger; Dror Avni; Yechezkel Sidi; Raya Leibowitz-Amit Journal: Transl Oncol Date: 2019-12-20 Impact factor: 4.243